BiondVax Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline.Since its inception, BiondVax has built a manufacturing facility for biopharmaceutical products and has executed eight clinical trials, including a seven-country, 12,400-participant phase 3 trial of its vaccine candidate.

The BiondVax team includes scientists, technicians, researchers, and administrative staff, and its GMP facility in Jerusalem houses the company's laboratories, production facilities, and offices.